While associations between the two conditions have been documented in the literature, a new study led by Cleveland Clinic investigators is the first to suggest a bidirectional link and to reveal the impact of IBD treatment on celiac disease.
Biosimilar Safety and Efficacy Comparable to Biologic Treatment in IBD Patients
Biologic compounds have long been considered the gold standard immunosuppressive therapy for moderate-to-severe IBD, but growing evidence suggests that biosimilars offer similar benefits at a much lower cost. Now, a new Cleveland Clinic study comparing the biologic compound infliximab with the biosimilar infliximab-abda shows that the two therapies are comparable in both safety and efficacy
Low-Dose Aspirin for Extended VTE Prophylaxis After IBD Surgery
Venous thromboembolism extended prophylaxis with low-dose aspirin after inflammatory bowel disease surgery is a safe and cost-effective strategy when compared with enoxaparin or no prophylaxis.
Impact of Biologics Use on Bone Loss in Patients with IBD
IBD patients treated with biologics are significantly less likely to have osteoporosis and bone fractures compared with those who did not, according to the largest individual study to date investigating the prevalence of osteoporosis and bone fractures in IBD patients with and without biologics therapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Recognizing Noninfectious Autoimmune Scleritis
When assessing a patient for “red-eye” with severe ocular pain, rheumatologists should have a high index of suspicion for scleritis. In this article, rheumatologist Rula Hajj-Ali, MD, discusses how to alleviate pain and prevent complications in inflammatory eye disease.
Risk of Deep Vein Thrombosis in Patients with IBD: Choosing a Catheter for Parenteral Nutrition
Tunneled catheters are safer than peripherally inserted catheters (PICCs) for IBD patients receiving home parenteral nutrition.
Managing Inflammatory Bowel Disease and Pancreaticobiliary Disorders in Patients With COVID-19
Guidelines for treating COVID-19 patients with IBD and pancreatic diseases.
TARGET-IBD Findings Demonstrate Need for Objective Evaluation Prior to Therapy Changes
Clinicians do not administer reactive TDM or objective disease activity assessments prior to making changes in biologic therapies in almost a third of patients with IBD.
COVID-19: Implications for Managing Inflammatory Bowel Disease
As of March 25, 2020, there were 87 reports of patients with IBD and COVID-19 in the international Surveillance Epidemiology of Coronavirus Under Research Exclusion database (SECURE-IBD).
A New Era of IBD Care
Cleveland Clinic’s enterprise-wide inflammatory bowel disease (IBD) program has entered a new era, combining novel medical and surgical therapies with pioneering research.